Nkarta (NKTX) Stifel 2024 Healthcare Conference summary

Clinical development strategy and trial updates

• Multiple clinical trials are active, including NTrust-1 for lupus nephritis and NTrust-2 for B-cell-mediated autoimmune diseases like myositis, scleroderma, and ANCA-associated vasculitis.

• Data readouts across all trials are expected in 2025, with a focus on presenting robust, aggregate data rather than individual patient case reports.

• The company collaborates closely with investigator-sponsored trials (ISTs), notably at Columbia, to broaden the understanding of lupus beyond nephritis.

• A compressed dosing regimen is being adopted across trials for greater patient convenience and improved pharmacokinetics.

• The platform aims to consolidate dosing schedules to streamline future development and commercial use.

Competitive landscape and positioning

• The field is highly competitive, with over 60 companies developing therapies for autoimmune diseases, but few are focused on engineered, off-the-shelf, allogeneic NK cell therapies.

• Strong relationships with physician-investigators and patient organizations enhance trial visibility and enrollment.

• Patient groups are highly aware of cell therapy options and are eager for new modalities, especially those that offer drug-free remission.

• Safety and accessibility are key differentiators, with NK cell therapies showing favorable profiles compared to CAR-T, particularly regarding toxicities like CRS and ICANS.

• The company is positioned to expand access to cell therapies in community settings, not just academic centers.

Safety, background therapy, and patient perspectives

• NK cell therapies are perceived as safer and more scalable than CAR-T, with fewer severe toxicities and better outpatient potential.

• There is ongoing education among rheumatologists and patients about the risks and benefits of lymphodepletion agents like fludarabine and cyclophosphamide.

• Women of childbearing potential and pediatric patients are especially sensitive to chemotherapy risks, influencing trial design and future product appeal.

• The NTrust-1 protocol includes guidance for tapering background immunosuppression and steroids, aiming for drug-free remission where possible.

• Patients are highly motivated to reduce or eliminate steroid use, and trial protocols are designed to accommodate gradual withdrawal.